←  Medicine & Diseases

LONGECITY


The above is an ad! Advertisements help to support the work of this non-profit organisation. To go ad-free join as a Member.
»

Rapid drug development with regulatory cof...

treonsverdery's Photo treonsverdery 18 May 2009

Rapid drug development with regulatory cofunctionals

Have congress deem hose dozen countries where the people have fewer measured deaths from medical treatment than the United States effective at pharmaceutical approval
That gives drug developers the ability to rapidly create new active pharmaceuticals

I truly believe that if places like Sweden or Japan approve a drug it is likely functional
Regarding risk, as these nations have fewer deaths from medical treatment their pharmaceutical screening process is deemable as cofunctional

This is a wonderful way to create more newer drugs while minimizing regulatory burden

A physician could just say things like I could prescribe Modacetam with a Swedish prescription protocol. You should know Sweden has just .8 of the US complication rate on prescribed medications as well as .89 on medically related deaths. That highly beneficial profile is better than the Unites States at 1. If you prefer the USFDA approved group I could prescribe piracetam with modafinil as separates yet the Swedish drug is three times as effective per gram possibly suggesting fewer side effects.

I mean this kindly
I truly believe giving physicians the ability to change the channel to medical protocols where people live longer would be of benefit

I personally favor a completely libertarian nonregulatory approach to pharmaceuticals
Edited by treonsverdery, 18 May 2009 - 08:36 PM.
Quote